Epicardial Adipose Tissue as a Metabolic Target to Improve Outcomes After Catheter Ablation for Atrial Fibrillation

Atrial fibrillation (AF) remains a major global health challenge, with high recurrence rates after catheter ablation despite advances in procedural techniques.Epicardial adipose tissue (EAT) has emerged as a metabolically active substrate that may adversely affect procedural outcomes through local paracrine and vasocrine effects.By secreting pro-inflammatory and pro-fibrotic mediators, EAT may lead to conduction heterogeneity, structural remodeling, and electrical instability in the left atrium.To further expand on this topic, studies evaluating the effect of antidiabetic agents, lipid-lowering therapies, and heart failure medications on EAT volume, attenuation, and inflammatory activity, as well as their association with post-ablation outcomes, were systematically reviewed and summarized.Evidence suggests that available therapies for diabetes, hyperlipidemia, and heart failure can reduce EAT volume and suppress its inflammatory profile, potentially leading to improved substrate characteristics.Such "upstream" interventions are associated with improved procedural outcomes and a reduction in AF recurrence following catheter ablation.These findings suggest that optimal long-term rhythm control is achieved through the synergy between advancements in ablation technology and targeted modification of the underlying metabolic and inflammatory substrate.Shifting the therapeutic focus toward EAT-directed interventions may offer a valuable framework for enhancing the durability of sinus rhythm after catheter ablation.The aim of this review is to provide an interpretive overview of available studies describing the molecular mechanisms linking EAT to AF pathophysiology.This review emphasizes the effects of various pharmacological therapies targeting cardiometabolic risk factors and their potential to modulate the biological activity of EAT and influence AF recurrence.